Cybin initiates first-in-human dosing of cyb004 in phase 1 clinical trial

Toronto--(business wire)--cybin inc. (neo:cybn) (nyse american:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that the first participants have been dosed with cyb004 in its ongoing three-part phase 1 clinical trial evaluating intravenous n,n-dimethyltryptamine (“iv dmt”) and cyb004 in healthy volunteers. as expected, robust psychedeli.
CYBN Ratings Summary
CYBN Quant Ranking